首页> 外文OA文献 >Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

【2h】

Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

机译：Mirabegron的安全性和疗效作为索尔替尼蛋白治疗过度活性膀胱患者的“加载项”治疗：日本营销后，开放标签研究（Milai学习）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Osamu Yamaguchi; Hidehiro Kakizaki; Yukio Homma; Yasuhiko Igawa; Masayuki Takeda; Osamu Nishizawa; Momokazu Gotoh; Masaki Yoshida; Osamu Yokoyama; Narihito Seki; Akira Okitsu; Takuya Hamada; Akiko Kobayashi; Kentarou Kuroishi;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study) [J] . Yamaguchi Osamu, Kakizaki Hidehiro, Homma Yukio, BJU international . 2015,第4期

机译：米拉贝隆在索非那新治疗的膀胱过度活动症患者中作为“附加”疗法的安全性和有效性：日本的一项上市后开放标签研究（MILAI研究）
2. Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study ( BESIDE) [J] . Wein Alan J. The Journal of Urology . 2017,第3aPta1期

机译：Re：Mirabegron加入治疗对失去的过活性膀胱蛋白的疗效和安全性，对初始4周索丙蛋白单疗法反应不足的患者：随机双盲多期相3B研究（旁边）
3. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE) [J] . Drake Marcus J., Chapple Christopher, Esen Ahmet A., European urology . 2016,第1期

机译：对于开始4周Solifenacin单药治疗反应不佳的失禁性膀胱过度活动症患者，Mirabegron联合Solifenacin疗法的疗效和安全性：一项随机双盲多中心3B研究（BESIDE）
4. Use of Electrical Stimulation of the Posterior Tibial Nerve in Patients with Bladder Hyperactivity as a Substitute for Pharmacological Therapy based on Solifenacin Succinate and Oxybutynin Hyloridrate [C] . Fabiana Bianchi Perez, Jose Natal de Souza, Nathalia Cristina Rosa, International Conference on Biomedical Electronics and Devices . 2016

机译：基于Solifencin琥珀酸盐和oxybutynin Hyloridrate的药理学治疗患者膀胱多动患者后胫骨神经电刺激的使用
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder [O] . Yankai Xu, Ruihua Liu, Chu Liu, 2017

机译：Mirabegron联合索非那新治疗膀胱过度活动症的疗效和安全性的Meta分析
7. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy:A Randomised, Double-blind, Multicentre, Phase 3b Study (BESIDE) [O] . Drake Marcus, Chapple Christopher, Esen Ahmet, 2016

机译：对于开始4周Solifenacin单药治疗反应不佳的失禁性膀胱过度活动症患者，Mirabegron联合Solifenacin疗法的疗效和安全性：一项随机，双盲，多中心，3b期研究（BESIDE）

Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)

著录项

引文网络

相似文献

相关主题

期刊订阅